Cargando…
An Open‐Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non‐Small Cell Lung Cancer
LESSONS LEARNED. The combination of bevacizumab with docetaxel‐gemcitabine resulted in unacceptable toxicity, particularly a high rate of pulmonary toxicity (30%). Despite promising efficacy, excessive toxicity of this regimen does not support its use in patients with advanced nonsquamous non‐small...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459252/ https://www.ncbi.nlm.nih.gov/pubmed/30602615 http://dx.doi.org/10.1634/theoncologist.2018-0857 |